NeOnc Technologies Holdings Inc. (Nasdaq: NTHI) announced newly published preclinical findings from a research collaboration at the University of Southern California (USC) demonstrating that ultrasound enhances the potency of NEO100 in treating primary and metastatic brain tumors. The study, available on bioRxiv, utilized an AI-driven, 3D-bioprinted platform to identify NEO100 as a promising agent for sonodynamic therapy. Validation studies on patient-derived tumor organoids showed increased antitumor activity when NEO100 was combined with focused ultrasound. The company indicated that these results support advancing NEO100 with focused ultrasound into future clinical trials across various brain tumor types. Results have already been presented in the published preclinical study.